P. D. Leeson and B. Springthorpe, The influence of drug-like concepts on decision-making in medicinal chemistry, Nat. Rev. Drug Discovery, vol.6, p.881, 2007.

C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Delivery Rev, vol.23, p.3, 1997.

C. A. Lipinski, Lead-and drug-like compounds: the rule-of-five revolution, Drug Discovery Today: Technol, vol.1, p.337, 2004.

M. Vieth, M. G. Siegel, R. E. Higgs, I. A. Watson, D. H. Robertson et al., Characteristic physical properties and structural fragments of marketed oral drugs, J. Med. Chem, p.224, 2004.

J. R. Proudfoot, The evolution of synthetic oral drug properties, Bioorg. Med. Chem. Lett, p.1087, 2005.

R. Morphy, The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds, J. Med. Chem, p.2969, 2006.

H. Van-de-waterbeemd, D. A. Smith, K. Beaumont, and D. K. Walker, Property-based design: optimization of drug absorption and pharmacokinetics, J. Med. Chem, p.1313, 2001.

M. D. Cronin and T. Mark, The role of hydrophobicity in toxicity prediction, Curr. Comput.-Aided Drug Des, vol.2, p.405, 2006.

N. A. Meanwell, Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety, Chem. Res. Toxicol, 1420.

S. R. Laplante, N. Aubry, G. Bolger, P. Bonneau, R. Carson et al., Monitoring drug selfaggregation and potential for promiscuity in off-target in vitro pharmacology screens by a practical NMR strategy, J. Med. Chem, vol.56, pp.7073-7083, 2013.

J. D. Hughes, J. Blagg, D. A. Price, S. Bailey, G. A. Decrescenzo et al., Physiochemical drug properties associated with in vivo toxicological outcomes, Bioorg. Med. Chem. Lett, vol.18, pp.4872-4875, 2008.

S. R. Laplante, R. Carson, J. Gillard, N. Aubry, R. Coulombe et al., Compound aggregation in drug discovery: implementing a practical NMR assay for medicinal chemists, J. Med. Chem, vol.56, pp.5142-5150, 2013.

J. Seidler, S. L. Mcgovern, T. N. Doman, and B. K. Shoichet, Identification and prediction of promiscuous aggregating inhibitors among known drugs, J. Med. Chem, vol.46, pp.4477-4486, 2003.

B. Y. Feng, A. Simeonov, A. Jadhav, K. Babaoglu, J. Inglese et al., A high-throughput screen for aggregation-based inhibition in a large compound library, J. Med. Chem, vol.50, 2007.

S. C. Owen, A. K. Doak, P. Wassam, M. S. Shoichet, and B. K. Shoichet, Colloidal Aggregation Affects the Efficacy of Anticancer Drugs in Cell Culture, ACS Chem. Biol, vol.7, pp.1429-1435, 2012.

S. C. Owen, A. K. Doak, A. N. Ganesh, L. Nedyalkova, C. K. Mclaughlin et al., Colloidal Drug Formulations Can Explain "Bell-Shaped" Concentration?Response Curves, ACS Chem. Biol, vol.9, pp.777-784, 2014.

Y. V. Frenkel, A. D. Clark, K. Das, Y. Wang, P. J. Lewi et al., Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability, J. Med. Chem, p.48, 1974.

A. N. Ganesh, E. N. Donders, B. K. Shoichet, and M. S. Shoichet, Colloidal aggregation: From screening nuisance to formulation nuance, Nano Today, vol.19, 2018.

J. Lu, S. C. Owen, M. S. Shoichet, J. Baik, and G. R. Rosania, Molecular imaging of intracellular drug?membrane aggregate formation, Macromolecules, vol.44, 1742.

N. E. Morrison and G. M. Marley, Clofazimine binding studies with deoxyribonucleic acid, Int J Lepr Other Mycobact Dis, vol.44, pp.475-481, 1976.

P. L. Beaulieu, G. Bolger, D. Deon, M. Duplessis, G. Fazal et al., Multi-parameter optimization of aza-follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 2: Impact of lipophilicity on promiscuity and in vivo toxicity, Bioorg. Med. Chem. Lett, p.1140, 2015.

S. R. Laplante, M. Bos, C. Brochu, C. Chabot, R. Coulombe et al., Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127), J. Med. Chem, p.1845, 2013.